Tim-3 decoy secreted by engineered cells to improve immunotherapy

Immunotherpay is being recognized as one of the most promising treatments for cancer. However, the success rate of these treatments has been low and a large number of cancers, such as CD19+ B-cell malignacies, remain refractory. In particular, CAR-T -cell therapy has emerged as an effective therapeutic approach for patients with cancer, and a number of emerging strategies hold promise for improving CAR-T-cell function and persistence. These include optimizing the design of CAR constructs, increasing the proportion of memory T cells, altering the TME through cytokine signaling, and overcoming immune checkpoint inhibition with immune checkpoint blockers, such as T cell immunoglobulin and mucin domain-containing protein 3 (TIM3).The present invention relates to the field of medicine. Particularly, the present invention relates to the field of therapies against cancer.